TGFB1 and metastatic neoplasm: In six patients undergoing therapy for metastatic disease, the study revealed a decrease in TGF-β1 levels (21 to 51%) for patients who responded to treatment and an increase in TGF-β1 levels (34 to 69%) for BC patients who failed to respond to systemic treatment.